- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00896779
Lucentis in Advanced Macular Degeneration
Patients with low vision (visual acuity 20/400 or worse) were excluded from the large Phase III ranibizumab clinical trials. It is not known if treatment with ranibizumab results in improved visual function in such patients.Since ranibizumab has been shown to be the most effective therapy for exudative macular degeneration we propose to treat all patients in this study with monthly ranibizumab intravitreal injections.
Patients will be assigned to one of two groups by the flip of a coin. Group #1 for "heads" and Group #2 for "tails".
Group #1 patients will be treated for 3 monthly injections of 0.5 mg of ranibizumab and then as needed therapy.
Group #2 will be treated with 6 monthly injections of 0.5 mg of ranibizumab and then as needed therapy.
Studieöversikt
Detaljerad beskrivning
The duration of the study is up to 13 months. This includes up to 30 days during which tests will be performed before treatment. Only one eye will be chosen for the study. Patients can receive up to 12 injections of ranibizumab during this study (the first dose[s], plus additional doses [re treatment as often as every 22 days] if the doctor determines that additional doses are required).
In addition to study drug injections. Several eye examinations and procedures will be performed to evaluate response to treatment. These include: visual acuity testing (eye chart), contrast sensitivity testing, reading speed testing, measurement of time to complete typical daily activities, measurement of the thickness of the central retina, measurement of your central visual field.
On the screening visit and two more times during the study fluorescein angiography will be performed.
The screening tests included the following:
- A review of your medical history
- A review of any medications you are or have been taking
- Eye examinations, including visual acuity testing (reading letters on an eye chart)
- Blood pressure measurement Woman of childbearing potential must also take a urine pregnancy test during the screening period to rule out pregnancy.
Upon completion of the study at Month 12 and if it were to occur; early termination visit, the following procedures will be performed: vision exam,OCT,microperimetry,FA/Photos,VFQ,reading performance, contrast sensitivity and TIADL.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
San Francisco, California, Förenta staterna, 94107
- California Pacific Medical Center
-
Stanford, California, Förenta staterna, 94305
- Stanford University School of Medicine
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Subjects will be eligible if the following criteria are met:
- Ability to provide written informed consent and comply with study assessments for the full duration of the study.
- Age > 50 years.
- Low vision AMD patients with a VA of 20/400 or worse.
- Evidence of active exudation as manifested by subretinal or intraretinal fluid on OCT or fresh appearing subretinal hemorrhage on fundus examination.
Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from this study:
- Pregnancy (positive pregnancy test) or lactation.
- Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
- Participation in another simultaneous medical investigation or trial.
- Concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy, advanced glaucoma).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: ranibizumab Group 1
Group 1: 3 monthly injections of 0.5mg then prn
|
Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months
Andra namn:
|
Övrig: ranibizumab Group 2
Group 2: 6 monthly injections of 0.5 mg then prn
|
Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Mean Change in Visual Acuity
Tidsram: 12 months
|
Change in vision from baseline measurement at 12 months.
Standard ETDRS chart (80 letters) was used to determine visual acuity with test luminance of 45 cd/m ^2 at 8 feet.
Number of correctly read letters were reported.
|
12 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Dr. Steven R. Sanislo, Stanford University
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SU-04202009-2338
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Makuladegeneration
-
Osias Francisco de SouzaOkändDegeneration av makula och bakre polBrasilien
-
Benha UniversityRekryteringMacula Lutea DegenerationFörenade arabemiraten
-
Alexandria UniversityAktiv, inte rekryterande
-
Technical University of MunichHar inte rekryterat ännu
-
Muğla Sıtkı Koçman UniversityAvslutadMenisk; DegenerationKalkon
-
NanoFUSE Biologics, LLCOkändBen; Degeneration
-
Institut Straumann AGAvslutadDegeneration; BenTyskland, Ungern, Belgien, Italien, Spanien, Sverige, Schweiz
-
3SpineRekryteringDegeneration av ländryggenFörenta staterna
-
Virtua Health, Inc.Avslutad
-
ElsanAvslutad
Kliniska prövningar på ranibizumab
-
University of Campania "Luigi Vanvitelli"Avslutad
-
University of Illinois at ChicagoGenentech, Inc.IndragenGlaukom | Neovaskulär glaukom | Nyuppstått glaukom | Nyuppstått neovaskulär glaukom
-
Lupin Ltd.RekryteringNeovaskulär åldersrelaterad makuladegenerationIndien
-
Hawaii Pacific HealthGenentech, Inc.AvslutadPolypoidal koroidal vaskulopati | PCVFörenta staterna
-
New England Retina AssociatesGenentech, Inc.AvslutadChoroidalt melanomFörenta staterna
-
Samsung Bioepis Co., Ltd.AvslutadÅldersrelaterad makuladegenerationKorea, Republiken av, Förenta staterna, Indien, Tyskland, Ungern, Storbritannien, Tjeckien, Polen, Ryska Federationen
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.AvslutadDiabetiskt makulaödemArgentina, Mexiko
-
Instituto de Olhos de GoianiaAvslutad
-
Vista KlinikAvslutadÅldersrelaterad makuladegeneration | Choroidal neovaskulariseringSchweiz
-
Pusan National University HospitalNovartisAvslutadExsudativ åldersrelaterad makuladegenerationKorea, Republiken av